NO960223L - 2,9-disubstituerte purin-6-oner - Google Patents

2,9-disubstituerte purin-6-oner

Info

Publication number
NO960223L
NO960223L NO960223A NO960223A NO960223L NO 960223 L NO960223 L NO 960223L NO 960223 A NO960223 A NO 960223A NO 960223 A NO960223 A NO 960223A NO 960223 L NO960223 L NO 960223L
Authority
NO
Norway
Prior art keywords
substituted
carbon atoms
purln
phenyl
straight chain
Prior art date
Application number
NO960223A
Other languages
English (en)
Other versions
NO960223D0 (no
Inventor
Ulrich Niewohner
Erwin Bischoff
Helmuth Schutz
Elisabeth Perzborn
Matthias Schramm
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of NO960223D0 publication Critical patent/NO960223D0/no
Publication of NO960223L publication Critical patent/NO960223L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28Oxygen atom
    • C07D473/30Oxygen atom attached in position 6, e.g. hypoxanthine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)

Abstract

2,9-dlsubstltuerte purln-6-oner fremstilles ved at man l et første trinn acyleres tilsvarende substituerte aminolmidazoler og deretter rlngslutter til purln. De nye 2,9-disubstltuerte purln-6-onene kan anvendes som virksomme stoffer l legemidler, spesielt for behandling av betennelser, tromboemboliske, hjerte- og kretsløps- sykdommer og sykdommer l urogenltalsystemet. O): A står for en rest med formelen eller for rettkjedet eller forgrenet alkyl med Inntil 20 karbonatomer, eller for cykloalkyl med 3 til 7 karbonatomer eller står for fenyl som eventuelt kan vare substituert Inntil 2 ganger likt eller forskjellig med halogen, karboksyl. trlfluormetyl, nltro. cyano eller med rettkjedet eller forgrenet alkyl, alkoksykarbonyl eller alkoksy med l et hvert tilfelle Inntil 5 karbonatomer, som l sin tur kan vare substituert med fenyl, og/eller syklusene er eventuelt substituert med fenyl som l sin tur kan vare substituert med rettkjedet eller forgrenet alkoksy med Inntil 5 karbonatomer.
NO960223A 1995-01-19 1996-01-18 2,9-disubstituerte purin-6-oner NO960223L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19501482A DE19501482A1 (de) 1995-01-19 1995-01-19 2,9-disubstituierte Purin-6-one

Publications (2)

Publication Number Publication Date
NO960223D0 NO960223D0 (no) 1996-01-18
NO960223L true NO960223L (no) 1996-07-22

Family

ID=7751830

Family Applications (1)

Application Number Title Priority Date Filing Date
NO960223A NO960223L (no) 1995-01-19 1996-01-18 2,9-disubstituerte purin-6-oner

Country Status (31)

Country Link
US (1) US5861404A (no)
EP (1) EP0722944A1 (no)
JP (1) JPH08231545A (no)
KR (1) KR960029334A (no)
CN (1) CN1135485A (no)
AR (1) AR002953A1 (no)
AU (1) AU4097996A (no)
BG (1) BG61728B1 (no)
BR (1) BR9600147A (no)
CA (1) CA2167353A1 (no)
CO (1) CO4700523A1 (no)
CZ (1) CZ16696A3 (no)
DE (1) DE19501482A1 (no)
EE (1) EE9600018A (no)
FI (1) FI960225A7 (no)
HR (1) HRP960007A2 (no)
HU (1) HUP9600106A3 (no)
IL (1) IL116769A (no)
MA (1) MA23778A1 (no)
NO (1) NO960223L (no)
NZ (1) NZ280830A (no)
PE (1) PE64996A1 (no)
PL (1) PL312354A1 (no)
SG (1) SG50401A1 (no)
SK (1) SK8096A3 (no)
SV (1) SV1996000006A (no)
TN (2) TNSN96007A1 (no)
TR (1) TR199600028A2 (no)
TW (1) TW314519B (no)
YU (1) YU1396A (no)
ZA (1) ZA96398B (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19529102A1 (de) * 1995-08-08 1997-02-13 Kummer Horst Dieter Verwendung von PDE-Inhibitoren bei der Behandlung von Harnblasenerkrankungen
US5824669A (en) * 1996-03-22 1998-10-20 Nitromed, Inc. Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
US5958926A (en) 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
USRE37234E1 (en) 1996-11-01 2001-06-19 Nitromed, Inc. Nitrosated and nitrosylated phosphodiestrase inhibitor compounds, compositions and their uses
WO1999003858A1 (en) * 1997-07-15 1999-01-28 Japan Energy Corporation Novel purine derivatives and medicinal use thereof
CA2309350C (en) * 1997-11-12 2007-04-03 Mitsubishi Chemical Corporation Purine derivatives and medicaments comprising the same as active ingredient
CA2315736A1 (en) * 1998-01-05 1999-07-15 Eisai Co., Ltd. Purine compounds and adenosine a2 receptor antagonist as preventive or therapeutic for diabetes mellitus
US6124303A (en) * 1998-09-11 2000-09-26 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 9-substituted 2-(2-N-aloxyphenyl) purin-6-ones
US6268372B1 (en) 1998-09-11 2001-07-31 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
CN1160355C (zh) * 1999-05-11 2004-08-04 三菱化学株式会社 嘌呤衍生物二水合物、含有该化合物作为有效成分的药物及其制备中间体
GB9924020D0 (en) 1999-10-11 1999-12-15 Pfizer Ltd Pharmaceutically active compounds
ATE552013T1 (de) * 2000-09-06 2012-04-15 Mitsubishi Tanabe Pharma Corp Zubereitungen zur oralen anwendung
EP1366760B1 (en) * 2001-02-15 2010-06-30 Mitsubishi Tanabe Pharma Corporation Tablets quickly disintegrated in oral cavity
US6479493B1 (en) 2001-08-23 2002-11-12 Cell Pathways, Inc. Methods for treatment of type I diabetes
US7208516B2 (en) 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7276529B2 (en) 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
CN102742513A (zh) * 2012-07-17 2012-10-24 南京熊猫机电制造有限公司 一种喂食栏装置
JP6687550B2 (ja) 2014-06-23 2020-04-22 セルジーン コーポレイション 肝疾患又は肝機能異常を治療するためのアプレミラスト
CA3134613A1 (en) 2019-04-02 2020-10-08 Aligos Therapeutics, Inc. Compounds targeting prmt5
JP7385467B2 (ja) * 2019-12-26 2023-11-22 キッセイ薬品工業株式会社 ヒポキサンチン化合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4451478A (en) * 1982-03-12 1984-05-29 Newport Pharmaceuticals International, Inc. Imidazole compounds
IL76546A (en) * 1984-10-12 1988-12-30 Warner Lambert Co 9-(heteroarylalkyl)-6-purine(thi)one derivatives,their preparation and pharmaceutical compositions containing them
GB9213623D0 (en) * 1992-06-26 1992-08-12 Pfizer Ltd Therapeutic agents

Also Published As

Publication number Publication date
NO960223D0 (no) 1996-01-18
US5861404A (en) 1999-01-19
AU4097996A (en) 1996-07-25
IL116769A (en) 1998-12-06
PE64996A1 (es) 1997-03-09
HU9600106D0 (en) 1996-03-28
MA23778A1 (fr) 1996-10-01
JPH08231545A (ja) 1996-09-10
BG100292A (bg) 1996-07-31
KR960029334A (ko) 1996-08-17
TR199600028A2 (tr) 1996-08-21
EE9600018A (et) 1996-08-15
BR9600147A (pt) 1998-01-06
IL116769A0 (en) 1996-05-14
FI960225A0 (fi) 1996-01-17
HRP960007A2 (en) 1998-02-28
CZ16696A3 (en) 1996-08-14
BG61728B1 (bg) 1998-04-30
CN1135485A (zh) 1996-11-13
HUP9600106A3 (en) 1998-04-28
EP0722944A1 (de) 1996-07-24
SG50401A1 (en) 1998-07-20
AR002953A1 (es) 1998-05-27
NZ280830A (en) 1998-04-27
SV1996000006A (es) 1996-10-29
CA2167353A1 (en) 1996-07-20
YU1396A (sh) 1999-03-04
CO4700523A1 (es) 1998-12-29
TW314519B (no) 1997-09-01
HUP9600106A2 (en) 1997-05-28
FI960225L (fi) 1996-07-20
SK8096A3 (en) 1996-08-07
FI960225A7 (fi) 1996-07-20
DE19501482A1 (de) 1996-07-25
TNSN96007A1 (fr) 2005-03-15
ZA96398B (en) 1996-08-28
PL312354A1 (en) 1996-07-22
TNSN96006A1 (fr) 2005-03-15

Similar Documents

Publication Publication Date Title
Hassimotto et al. Inhibition of Carrageenan‐Induced Acute Inflammation in Mice by Oral Administration of Anthocyanin Mixture from Wild Mulberry and Cyanidin‐3‐Glucoside
Hintz et al. Wavelength-dependent pathways of poly-3-hexylthiophene photo-oxidation
ATE495162T1 (de) Azabicyclo-octan und nonan derivate mit ddp-iv hemmender wirkung
ATE417051T1 (de) Polymorphe von clopidogrel-hydrogensulfat
NO20060279L (no) Thienopyridonderivater som kinaseinhibitorer
NO20083739L (no) Tieno-pyridinderivater som MEK-inhibitorer
EA200401294A1 (ru) Производные хинолина и изохинолина, способ их получения и их применение в качестве ингибиторов воспаления
ATE353361T1 (de) Gezielten modifikation der chromatinstruktur
DE69720735D1 (de) Immunotherapeutische mittel und ihre anwendung in der reduzierung der cytokininwerte
DK0820438T3 (da) O-carbamoyl-phenylalaninol med substituent på benzenringen, dens farmaceutisk egnede salte og fremgangsmåde til fremstilling af samme
NO20062357L (no) Indolinderivater og anvendelse av dem ved behandling av sykdomstilstander som cancer
IS7550A (is) Aðferð til framleiðslu á kvínólín-afleiðum
BR9907788A (pt) Agentes antiinflamatórios seletivos paraglicocorticóides
DE69735634D1 (de) Substituierte cyclopentanderivate die als neuramidase-inhibitoren nuetzlich sind
PE20060335A1 (es) Prolina cci-779, su produccion y sintesis enzimatica de dos etapas de prolina cci-779 y cci-779
FR2841562B1 (fr) Composition retardatrice d'inflammation, procede de preparation de cette composition, et procede de retardement d'incendies en terrain sauvage utilisant cette composition
NO20093014L (no) Taxanderivater og fremgangsmater ved fremstilling derav
Kahveci et al. Microwave‐Assisted Synthesis of Some Novel Benzimidazole Derivatives Containing Imine Function and Evaluation of Their Antimicrobial Activity
DK0869965T3 (da) Steroidnitritesterderivater anvendelige som antiinflammatoriske lægemidler
GEP20084477B (en) NEW BENZAMIDES AS PPARγ MODULATORS
ES263127A1 (es) Un procedimiento para la fabricaciën de derivados de 1,4-benzodiazepinas
CA2292775A1 (en) Cyanoguanidines as cell proliferation inhibitors
WO2007145707A3 (en) Use of non-hydroxide bases with heat for relaxing or straightening hair
GB1113530A (en) Production of 3-substituted phthalimidines
ATE409191T1 (de) 1,3-diaza-dibenzoazulene als inhibitoren der produktion von tumornekrosefaktor und zwischenprodukte für deren herstellung